Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson's, epilepsy, schizophrenia and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Company profile
Ticker
CERE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARYA Sciences Acquisition Corp II
SEC CIK
CERE stock data
Analyst ratings and price targets
Current price
Average target
$39.00
Low target
$28.00
High target
$48.00
JP Morgan
Maintains
$40.00
Mizuho
Maintains
$28.00
HC Wainwright & Co.
Maintains
$48.00
Loop Capital
Initiated
$40.00
Latest filings (excl ownership)
8-K
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
9 Jan 23
8-K
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
19 Dec 22
EFFECT
Notice of effectiveness
21 Nov 22
CORRESP
Correspondence with SEC
16 Nov 22
UPLOAD
Letter from SEC
10 Nov 22
S-3
Shelf registration
8 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
8 Nov 22
8-K
Entry into a Material Definitive Agreement
16 Aug 22
8-K
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
12 Aug 22
Transcripts
CERE
Earnings call transcript
2022 Q3
13 Nov 22
CERE
Earnings call transcript
2022 Q2
1 Aug 22
CERE
Earnings call transcript
2022 Q1
14 May 22
CERE
Earnings call transcript
2021 Q4
1 Mar 22
CERE
Earnings call transcript
2021 Q3
10 Nov 21
CERE
Earnings call transcript
2021 Q2
11 Aug 21
CERE
Earnings call transcript
2021 Q1
17 May 21
CERE
Earnings call transcript
2020 Q4
24 Mar 21
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 250.47 mm | 250.47 mm | 250.47 mm | 250.47 mm | 250.47 mm | 250.47 mm |
| Cash burn (monthly) | (no burn) | 35.28 mm | 33.31 mm | 27.50 mm | 26.80 mm | 21.54 mm |
| Cash used (since last report) | n/a | 137.91 mm | 130.21 mm | 107.48 mm | 104.76 mm | 84.18 mm |
| Cash remaining | n/a | 112.56 mm | 120.26 mm | 142.99 mm | 145.71 mm | 166.28 mm |
| Runway (months of cash) | n/a | 3.2 | 3.6 | 5.2 | 5.4 | 7.7 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 116 |
| Opened positions | 19 |
| Closed positions | 14 |
| Increased positions | 58 |
| Reduced positions | 19 |
| 13F shares | Current |
|---|---|
| Total value | 6.58 bn |
| Total shares | 218.19 mm |
| Total puts | 313.20 k |
| Total calls | 339.50 k |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Bain Capital Investors | 60.63 mm | $1.71 bn |
| BC Perception | 60.63 mm | $1.94 bn |
| PFE Pfizer | 27.35 mm | $957.50 mm |
| FMR | 23.32 mm | $658.90 mm |
| Perceptive Advisors | 6.51 mm | $184.02 mm |
| Vanguard | 5.87 mm | $166.00 mm |
| T. Rowe Price | 4.77 mm | $134.78 mm |
| BLK Blackrock | 4.19 mm | $118.36 mm |
| FHI Federated Hermes | 3.31 mm | $93.64 mm |
| Rock Springs Capital Management | 2.50 mm | $70.63 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Jan 23 | Coles N Anthony | Common Stock | Sell | Dispose S | No | Yes | 30.732 | 500 | 15.37 k | 2,704 |
| 5 Jan 23 | Coles N Anthony | Common Stock | Sell | Dispose S | No | Yes | 29.9294 | 49,500 | 1.48 mm | 3,204 |
| 5 Jan 23 | Coles N Anthony | Common Stock | Option exercise | Acquire M | No | Yes | 3.5 | 50,000 | 175.00 k | 52,704 |
| 5 Jan 23 | Coles N Anthony | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 3.5 | 50,000 | 175.00 k | 3,002,417 |
| 9 Dec 22 | Coles N Anthony | Common Stock | Sell | Dispose S | No | Yes | 27.0932 | 5,145 | 139.39 k | 2,704 |
| 9 Dec 22 | Coles N Anthony | Common Stock | Sell | Dispose S | No | Yes | 26.617 | 44,855 | 1.19 mm | 7,849 |
| 9 Dec 22 | Coles N Anthony | Common Stock | Option exercise | Acquire M | No | Yes | 3.5 | 50,000 | 175.00 k | 52,704 |
| 9 Dec 22 | Coles N Anthony | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 3.5 | 50,000 | 175.00 k | 3,052,417 |
| 1 Nov 22 | John Renger | Common Stock | Sell | Dispose S | No | Yes | 30.0002 | 25,000 | 750.01 k | 2,704 |
| 1 Nov 22 | John Renger | Common Stock | Option exercise | Acquire M | No | Yes | 10.28 | 14,982 | 154.01 k | 27,704 |
News
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
19 Dec 22
Data Shows Cerevel's Emraclidine Does Not Induce High Blood Pressure In Schizophrenia Patients
19 Dec 22
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
19 Dec 22
Cerevel Reports Results In Emraclidine Ambulatory Blood Pressure Monitoring Trial; Co. Reports 'Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia'
19 Dec 22
Reported Late Thursday, Cerevel Therapeutics Announces Publication In The Lancet Of Emraclidine Data From Phase 1b Clinical Trial In People Living With Schizophrenia
16 Dec 22
Press releases
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
9 Jan 23
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
4 Jan 23
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
19 Dec 22
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
15 Dec 22
Cerevel Therapeutics to Present at Upcoming Investor Conferences
11 Nov 22